Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind Study of Palonosetron with or without Dexamethasone on Days 2 and 3 for Prevention of MEC-induced Nausea and Vomiting in Breast Cancer
2005-002643-89Phase 4Completed
- Sponsor
- Helsinn
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of palonosetron in breast cancer and chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Helsinn. Primary endpoint: Primary efficacy endpoint. Started Oct 2005; status: completed.
02
Drugs
palonosetron
03
Conditions
breast cancerchemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2005-002643-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002643-89.